Funding for this research was provided by:
Patient-Centered Outcomes Research Institute (ME 1303 5785)
Received: 14 November 2017
Accepted: 2 May 2018
First Online: 12 June 2018
Ethics approval and consent to participate
: This study was approved by the Johns Hopkins Bloomberg School of Public Health Institutional Review Board. Part 1 received an exemption (IRB no 00006356) and part 2 received an exemption (IRB no 00006324).
: Up to 2008, Kay Dickersin served as an unpaid expert witness for the plaintiffs’ lawyers in litigation against Pfizer that provided several gabapentin documents used for this study. The TMJ Association, Ltd., received funding from Pfizer in 2009–2011 (for the Campaign to End Chronic Pain in Women) and from Purdue Pharma, L.P., in 2008, 2010, and 2012–2016 (to support the TMJ Association science meeting and develop educational materials based on scientific research advances).
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.